Fragile X syndrome future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{Fragile X syndrome}} | {{Fragile X syndrome}} | ||
There are some medications under trials such as fenobam (mGLUR5 antagonist) and Lithium (mGLUR5 signaling inhibitor). | There are some [[medications]] under trials such as [[fenobam]] (mGLUR5 [[antagonist]]) and [[Lithium]] (mGLUR5 signaling [[inhibitor]]). | ||
== References == | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Latest revision as of 11:11, 3 January 2022
Fragile X syndrome Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Fragile X syndrome future or investigational therapies On the Web |
American Roentgen Ray Society Images of Fragile X syndrome future or investigational therapies |
FDA on Fragile X syndrome future or investigational therapies |
CDC on Fragile X syndrome future or investigational therapies |
Fragile X syndrome future or investigational therapies in the news |
Blogs on Fragile X syndrome future or investigational therapies |
Risk calculators and risk factors for Fragile X syndrome future or investigational therapies |
There are some medications under trials such as fenobam (mGLUR5 antagonist) and Lithium (mGLUR5 signaling inhibitor).